Clinical Trial Update: Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy [Phase 1]

View source ↗

Summary

A Phase 1 trial of INC280 (capmatinib) in combination with Cetuximab in MET-positive adult patients with metastatic colorectal cancer or head and neck squamous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Squamous Cell Carcinoma of Head and Neck

Drugs mentioned

• Cetuximab (cetuximab)
• INC280

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer | Phase 1 | Status: TERMINATED